Is TRT Safe for Your Heart? What the TRAVERSE Trial Found
Forbes Health Advisory Board · Naturopathic Doctor
If you've been researching testosterone replacement therapy, you've probably come across the heart risk question. It's the first thing most men ask. "Will this give me a heart attack?" It's a fair question. And for years, the answer was muddled by outdated studies, media headlines, and a warning label that scared patients away from treatment they actually needed.
That changed. A landmark clinical trial of 5,246 men, the largest and most rigorous study ever designed to answer this exact question, found no increased risk of heart attack or stroke in men receiving TRT. The FDA removed its boxed cardiovascular warning in February 2025. And in 2026, a European expert panel formally declared TRT cardiovascular-safe for men with confirmed low testosterone.
Here is what the research actually says, where the old fears came from, and what it means for you.
The Study That Settled the Debate
The TRAVERSE trial was published in the New England Journal of Medicine. It enrolled 5,246 men between the ages of 45 and 80, all of whom had clinically confirmed hypogonadism (low testosterone) and either pre-existing cardiovascular disease or significant risk factors for it. These were not healthy 30-year-olds. The trial deliberately selected a high-risk population to stress-test the safety question.
Men were randomized to receive either testosterone gel or a placebo. Researchers tracked them for an average of 22 months, measuring major adverse cardiovascular events (MACE): heart attacks, strokes, and cardiovascular death.
The result: no significant difference between the testosterone group and the placebo group. Men receiving TRT did not have more heart attacks. They did not have more strokes. They did not die from cardiovascular causes at a higher rate.
A meta-analysis covering more than 8,000 men across multiple studies confirmed the same finding. The cardiovascular risk that had been attached to TRT for over a decade was not supported by prospective, controlled research.
Where the Fear Came From
The TRT heart scare did not come from nowhere. Two studies in the early 2010s raised alarms, and they spread fast.
The first was the TOM trial in 2010. It enrolled elderly men (average age 74) with severe physical limitations and multiple chronic conditions. The trial was stopped early after the testosterone group showed more cardiovascular events than the placebo group. But the study had major limitations. It was small (209 men). The population was extremely frail. And the testosterone doses used were higher than standard clinical practice.
The second was a 2013 retrospective study of VA hospital records. It found higher cardiovascular event rates in men prescribed testosterone. But retrospective studies look backward through medical charts. They cannot control for the dozens of variables that prospective trials like TRAVERSE are designed to manage. Selection bias, undiagnosed conditions, inconsistent dosing, and incomplete records all contaminate the data.
These two studies generated headlines. The FDA responded in 2015 by adding a class-wide warning to all testosterone products about potential cardiovascular risk. That warning shaped a decade of patient fear and provider hesitation.
Then the TRAVERSE trial was specifically designed to answer the question those earlier studies could not. Prospective. Randomized. Placebo-controlled. In a high-risk population. And it found no elevated risk.
The FDA Removed the Warning
In February 2025, the FDA formally removed the boxed warning for major cardiovascular events from testosterone products. This was a significant regulatory reversal. Boxed warnings are the FDA's most serious safety designation, and removing one signals a meaningful shift in the evidence base.
The FDA replaced it with a narrower class-wide warning about potential blood pressure increases. That is a manageable clinical concern, not a reason to avoid treatment. It means your provider should monitor your blood pressure while you're on TRT, which any responsible clinic already does.
The European Expert Panel Confirmed It
In 2026, the European Expert Panel for Testosterone Research (PaTeR) published a formal position statement in the journal Andrology (2026;14:294-302). Their conclusion: TRT is cardiovascular-safe when prescribed to men with clinically confirmed hypogonadism.
This panel reviewed the full body of evidence, including the TRAVERSE trial and the 8,000+ patient meta-analysis. Their position statement represents the current medical consensus from researchers who specialize in testosterone therapy.
What This Means If You Have Low Testosterone
If your testosterone is clinically low and you've been hesitant because of heart concerns, the data is now clear. In men with confirmed hypogonadism, TRT does not increase heart attack or stroke risk. The FDA agrees. The European expert panel agrees. The largest prospective trial ever conducted on the question agrees.
That does not mean TRT is risk-free. Every medical intervention has potential side effects. Testosterone therapy can affect red blood cell count, blood pressure, and other markers. That is exactly why ongoing monitoring matters.
The difference between responsible TRT and reckless TRT is follow-up. A provider who prescribes testosterone and never checks your labs again is not managing your care. A provider who monitors your bloodwork regularly, tracks your cardiovascular markers, and adjusts your protocol based on your response is doing it right.
How TRT Works at Med Matrix
We've treated over 3,000 patients at Med Matrix in South Portland, Maine. A large portion of our male patients come in specifically for testosterone replacement therapy, and the heart safety question comes up in nearly every consultation.
Our approach follows the same model the research supports: confirm the diagnosis with thorough testing, treat with individualized protocols, and monitor continuously.
Testing That Goes Beyond Total Testosterone
Most primary care doctors check total testosterone and call it a day. If the number falls within the reference range (roughly 300 to 1,000 ng/dL), you're told you're fine. That range is enormous. A 38-year-old man sitting at 320 is "technically normal" but functioning at the hormonal level of someone decades older.
Our 80+ biomarker panel includes total testosterone, free testosterone, SHBG, estradiol, DHEA, full thyroid, fasting insulin, inflammatory markers, lipid breakdown, and body composition analysis. We look at the complete picture because hormone imbalance rarely exists in isolation. Thyroid, metabolic health, inflammation, and nutrient status all interact with testosterone levels.
Individualized Treatment, Not a One-Size Protocol
TRT at Med Matrix is not a prescription printed from a template. Your provider reviews your labs, health history, symptoms, and goals during a full 60-minute consultation. Together, you build a plan that accounts for your specific numbers and your lifestyle.
Some men need testosterone alone. Others need thyroid support, metabolic optimization, or peptide therapy alongside TRT to get the full result. That is what a functional medicine approach looks like. Not treating a single number, but treating the whole system.
Ongoing Monitoring That Catches Problems Early
The blood pressure note in the FDA's updated labeling is a perfect example of why monitoring matters. Blood pressure can increase on TRT. So can hematocrit (red blood cell concentration). Both are easily tracked with regular lab work. If either moves outside a safe range, your provider adjusts the protocol.
Our ongoing care program means you're not left on your own after the first prescription. You have regular check-ins, follow-up labs, and direct access to your care team. That continuous relationship is what separates responsible hormone management from the mail-order testosterone model that skips the follow-up.
Signs You Might Have Low Testosterone
Low testosterone does not always announce itself with obvious symptoms. Many men live with it for years, attributing the changes to stress, aging, or poor sleep. Common signs include:
- Persistent fatigue that sleep does not fix
- Declining muscle mass or increased body fat despite regular exercise
- Brain fog, difficulty concentrating, or memory issues
- Low mood, irritability, or loss of motivation
- Reduced libido or erectile dysfunction
- Poor sleep quality or frequent waking
- Joint pain or slow recovery from workouts
- Hair thinning or changes in body hair
If several of these sound familiar, it is worth getting tested. Not a basic panel with just total testosterone. A full workup that shows what is actually happening.
Frequently Asked Questions
Does TRT cause heart attacks?
The TRAVERSE trial, the largest prospective study on this question (5,246 men, average 22-month follow-up), found no increased risk of heart attack or stroke in men receiving TRT. The FDA removed its boxed cardiovascular warning from testosterone products in February 2025 based on this evidence.
Is testosterone therapy safe for men with heart disease?
The TRAVERSE trial specifically enrolled men with pre-existing cardiovascular disease or high cardiovascular risk. Even in this high-risk population, TRT did not increase major adverse cardiovascular events. Your provider should still monitor blood pressure and cardiovascular markers during treatment.
Why did the FDA have a heart risk warning on testosterone?
The warning was added in 2015 based on two earlier studies (the TOM trial and a retrospective VA hospital study) that suggested a possible link. Both had significant methodological limitations. The TRAVERSE trial, designed specifically to address those limitations, did not find the same risk. The FDA removed the major CV event warning in 2025.
What blood tests do I need before starting TRT?
A responsible TRT evaluation goes beyond total testosterone. At Med Matrix, our 80+ biomarker panel includes free testosterone, SHBG, estradiol, DHEA, full thyroid markers, fasting insulin, inflammatory markers, a detailed lipid panel, and body composition analysis. This complete picture ensures your provider understands the full context before prescribing treatment.
How does Med Matrix monitor patients on TRT?
Every patient on TRT at Med Matrix receives ongoing follow-up care. That includes regular lab work to track testosterone levels, hematocrit, blood pressure, and cardiovascular markers. If anything moves outside a safe range, your provider adjusts the protocol. You also have direct access to your care team between visits.
Take the First Step
If low testosterone has been affecting your energy, your body, and your quality of life, and heart safety concerns have been holding you back, the evidence is clear. TRT does not increase cardiovascular risk when properly prescribed and monitored.
Our team of 7 providers at Med Matrix has worked with over 3,000 patients. We start with thorough testing, build individualized treatment plans, and stay with you through the entire process.
Get your free guide and $100 voucher to start with the testing that shows what is actually going on. Or book your first visit to talk with our team directly.